Zepbound Lawsuit Update: Injuries, Recall Status, and Legal Options

Federal litigation involving GLP-1 medications includes claims concerning severe gastrointestinal complications and NAION. On November 9, 2026, the U.S. Food and Drug Administration (FDA) announced new class-wide labeling requirements addressing a potential increased risk of NAION.

Patients diagnosed with serious gastrointestinal complications or NAION after taking Zepbound may have grounds for an individualized legal evaluation. However, a diagnosis following treatment does not establish that Zepbound caused the condition or that Eli Lilly is legally responsible.

Quick Facts

• Medication: Zepbound (tirzepatide), manufactured by Eli Lilly and Company.
• Targeted injuries: Gastroparesis, intestinal obstruction/ileus, and non-arteritic anterior ischemic optic neuropathy (NAION).
• FDA warnings: Zepbound labeling addresses severe gastrointestinal reactions, while new FDA requirements address a potential increased NAION risk.
• Litigation: Federal MDL 3094 involves gastrointestinal injuries, while MDL 3163 involves NAION-related allegations.

Latest News on the Zepbound Lawsuit

November 2026

On November 9, 2026, the FDA announced that manufacturers of GLP-1 medications must update their warnings to address a potential increased risk of NAION. The agency specifically identified Zepbound, which contains tirzepatide, among the medications subject to the new labeling requirements [1].

The FDA evaluated 126 randomized clinical trials involving 134,253 participants. Its analysis identified NAION rates of 6.4 cases per 100,000 person-years among GLP-1 users compared with 3.8 cases per 100,000 person-years among comparator patients.

The findings concern GLP-1 medications collectively and do not establish a Zepbound-specific incidence rate. FDA also reviewed observational studies, postmarketing reports, and other evidence before determining that additional warnings were warranted.

The agency advises patients experiencing sudden, painless vision changes to contact a healthcare professional immediately. Healthcare providers should promptly evaluate suspected NAION and consider discontinuing the medication when appropriate.

August 2026

Zepbound’s prescribing information, revised in August 2026, identifies severe gastrointestinal adverse reactions and states that the medication is not recommended for patients with severe gastroparesis. It also lists ileus, intestinal obstruction, and severe constipation among adverse reactions reported after tirzepatide entered the market [2].

Postmarketing reports do not establish how frequently these conditions occur or prove causation in individual patients. However, the labeling provides important safety information relevant to gastrointestinal injury allegations involving Zepbound.

July 2026

On July 2, 2026, the U.S. District Court for the Eastern District of Pennsylvania issued a case management order addressing pretrial proceedings in GLP-1 NAION litigation, MDL 3163. The order identifies Zepbound among the medications involved in allegations of sudden vision loss [3].

The court reported more than 130 cases in the proceeding as of a June 23, 2026 hearing. That figure includes allegations involving multiple GLP-1 medications and should not be interpreted as the number of Zepbound-specific lawsuits or the current litigation total.

May 2026

On May 18, 2026, the federal court overseeing GLP-1 gastrointestinal injury litigation issued a memorandum addressing the scope of expert testimony in MDL 3094. The court identified Zepbound, Mounjaro, and Trulicity as Eli Lilly medications involved in the proceeding [4].

The proceeding includes disputes over general causation involving gastroparesis, ileus, small bowel obstruction, and gallbladder injuries. The May memorandum addressed an expert-disclosure dispute and did not resolve whether Zepbound caused any individual plaintiff’s injuries.

Event	Month/Year	Type	Status	Source	Notes
FDA NAION safety communication	November 2026	Regulatory action	Announced	[1]	Class-wide warning changes required
Zepbound prescribing information	August 2026	Drug labeling	Revised	[2]	Gastrointestinal safety information documented
NAION litigation order	July 2026	Federal litigation	Pretrial proceedings	[3]	MDL 3163 includes Zepbound
Gastrointestinal litigation memorandum	May 2026	Federal litigation	Pretrial proceedings	[4]	Expert testimony dispute addressed

What Is Zepbound?

Zepbound is a prescription medication containing tirzepatide, manufactured by Eli Lilly and Company. The FDA approved Zepbound for chronic weight management in qualifying adults in 2023 and subsequently approved it for moderate to severe obstructive sleep apnea in adults with obesity.

Tirzepatide activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These actions influence blood sugar regulation, appetite, food intake, and gastric emptying.

Zepbound is administered by subcutaneous injection, generally once weekly. Its active ingredient is also used in Mounjaro, although the medications have different approved indications and labeling histories.

What’s the Problem With Zepbound?

The central concern in Zepbound litigation is whether tirzepatide contributed to serious gastrointestinal or ophthalmic injuries and whether patients and healthcare providers received adequate warnings. Plaintiffs allege that certain risks were not sufficiently communicated before patients experienced significant medical complications.

Zepbound delays gastric emptying, which can contribute to gastrointestinal symptoms during treatment. Its labeling recognizes severe gastrointestinal adverse reactions, while federal litigation examines allegations involving gastroparesis, ileus, and intestinal obstruction.

Separately, the FDA has identified a potential increased NAION risk across GLP-1 medications and required additional warnings. The evidence supporting gastrointestinal and vision-related concerns differs, and neither an adverse-event report nor a regulatory warning automatically proves causation in an individual patient.

What Injuries Are Being Investigated in Zepbound Lawsuits?

Zepbound litigation addresses several distinct medical conditions involving the digestive tract and optic nerve. Each condition requires an appropriate diagnosis and individualized evaluation of medication exposure, medical history, and alternative causes.

1. Gastroparesis (Stomach Paralysis)

Gastroparesis occurs when the stomach empties food abnormally slowly without a mechanical blockage. Symptoms may include persistent nausea, vomiting, bloating, abdominal discomfort, and feeling full after consuming small amounts of food.

Zepbound delays gastric emptying as part of its pharmacological action. Its prescribing information specifically states that the medication is not recommended for patients with severe gastroparesis.

However, delayed stomach emptying during treatment does not automatically establish a diagnosis of persistent gastroparesis. A clinical evaluation may include gastric-emptying testing and consideration of diabetes, other medications, or unrelated gastrointestinal disorders.

Severe cases can involve dehydration, inadequate nutrition, hospitalization, and substantial disruption of daily activities. The duration and cause of symptoms are important considerations when evaluating a potential injury claim.

2. Intestinal Blockage and Ileus

Intestinal obstruction occurs when material cannot move normally through the intestines because of a physical blockage. Ileus generally involves impaired intestinal movement without the same type of mechanical obstruction.

Symptoms may include severe abdominal pain, swelling, vomiting, constipation, and inability to pass gas or stool. Some patients require hospitalization, intravenous fluids, intestinal decompression, or surgery.

Zepbound’s August 2026 prescribing information lists ileus, intestinal obstruction, and severe constipation, including fecal impaction, among postmarketing adverse reaction reports. These reports are voluntarily submitted and cannot reliably establish frequency or causation.

Patients experiencing persistent vomiting, severe abdominal pain, or inability to pass gas or stool should seek urgent medical evaluation. Suspected intestinal obstruction can become a medical emergency.

3. NAION and Sudden Vision Loss

Non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to the front portion of the optic nerve becomes inadequate. The condition can cause sudden, painless vision loss, usually affecting one eye.

Symptoms may include blurred vision, blind spots, missing portions of the visual field, color distortion, or reduced central vision. Some patients first notice symptoms upon waking.

The FDA’s November 2026 communication identifies a potential increased NAION risk involving GLP-1 medications, including Zepbound. However, the agency’s pooled findings do not establish the risk attributable specifically to Zepbound or prove that tirzepatide caused a particular patient’s vision loss.

Other NAION risk factors include diabetes, hypertension, sleep apnea, smoking, anemia, and kidney disease. Sudden vision loss requires immediate medical attention and prompt ophthalmologic evaluation.

What Does the FDA Say About Zepbound Side Effects?

Zepbound’s prescribing information identifies gastrointestinal reactions including nausea, vomiting, diarrhea, constipation, abdominal pain, and dyspepsia. It also warns that some gastrointestinal adverse reactions can be severe.

In two clinical trials involving weight reduction, severe gastrointestinal adverse reactions occurred in 1.7% of patients receiving 5 mg, 2.5% receiving 10 mg, and 3.1% receiving 15 mg of Zepbound, compared with 1% receiving placebo.

These percentages describe severe gastrointestinal adverse reactions generally, not the incidence of gastroparesis or intestinal obstruction. They should not be interpreted as the likelihood that an individual patient will develop either condition.

The FDA’s November 9, 2026 communication additionally requires GLP-1 manufacturers to address the potential increased risk of NAION in product labeling. Patients should discuss medication benefits, risks, and treatment decisions with their prescribing clinicians.

Are There Active Zepbound Lawsuits?

Yes. Federal court records identify Zepbound in two multidistrict litigation proceedings involving allegations of gastrointestinal injury and NAION. Both proceedings are before the U.S. District Court for the Eastern District of Pennsylvania.

• MDL 3094: Addresses allegations involving gastroparesis, ileus, intestinal obstruction, and other gastrointestinal injuries associated with GLP-1 medications.
• MDL 3163: Addresses allegations that GLP-1 medications caused NAION and associated vision loss.

Multidistrict litigation coordinates related federal lawsuits for pretrial proceedings. It is not necessarily a class action, and individual claims may retain distinct medical histories, damages, and legal issues.

The existence of these proceedings does not establish that Eli Lilly is liable for the alleged injuries. Causation, the adequacy of warnings, and applicable legal defenses remain important issues.

Could Eli Lilly Be Liable for Zepbound Injuries?

Patients may pursue product-liability claims alleging that a medication was defective or that its manufacturer failed to provide adequate warnings about serious risks. Depending on applicable law, potential theories include failure to warn, defective design, negligence, or breach of warranty.

Plaintiffs may argue that earlier or stronger warnings would have affected prescribing or treatment decisions. Eli Lilly and other defendants may dispute causation, the adequacy of existing warnings, and whether particular claims are barred by federal preemption.

The FDA’s labeling actions and the pending lawsuits provide relevant regulatory and legal context but do not independently establish liability. Each claim requires evidence supporting the applicable legal elements, including a sufficient connection between the medication and alleged injury.

Who May Be Affected by the Zepbound Lawsuit?

Potentially affected patients include individuals who developed medically documented gastroparesis, intestinal obstruction/ileus, or NAION after using Zepbound. Some may have experienced hospitalization, prolonged gastrointestinal treatment, or permanent visual impairment.

The timing of symptoms, treatment duration, dosage history, preexisting conditions, and diagnostic findings may influence an individual’s case. Patients with diabetes, prior gastrointestinal disorders, or established NAION risk factors may require additional medical evaluation to assess other possible causes.

Individuals who suffered serious complications may wish to obtain legal guidance about their circumstances and available documentation. A diagnosis occurring after medication use does not automatically establish that the medication caused the condition.

Do I Qualify for a Zepbound Lawsuit?

The following questions may help determine whether a potential Zepbound injury claim warrants further legal evaluation:

• Were you prescribed Zepbound and did you use it before the onset of your reported injury?
• Were you diagnosed with gastroparesis, intestinal obstruction, ileus, or NAION by a qualified healthcare professional?
• Did the condition cause hospitalization, significant medical expenses, permanent vision loss, or another serious consequence?
• Do you have prescription records, diagnostic tests, medical documentation, or other evidence supporting your treatment and injury timeline?

Answering yes does not establish eligibility or guarantee compensation. An attorney can evaluate medical causation, historical drug labeling, legal defenses, damages, and applicable filing deadlines.

What Evidence Is Important in a Zepbound Lawsuit?

Medical records and prescription documentation may be important when determining whether a claim is legally viable. Relevant materials include:

• Zepbound prescription records and pharmacy documentation
• Medication dosage and treatment history
• Dates of symptom onset and medical diagnosis
• Gastroenterology evaluations and gastric-emptying studies
• Imaging and hospital records involving bowel obstruction
• Ophthalmology records and visual-field testing
• Prior medical conditions and medication history
• Medical expenses and employment documentation

Establishing a clear timeline between treatment, symptoms, diagnostic testing, and medical care may assist an investigation. Medical experts may also need to evaluate alternative explanations for the reported injury.

What Compensation May Be Available?

Potential damages in a qualifying Zepbound lawsuit may include medical expenses, future treatment costs, lost income, diminished earning capacity, pain and suffering, and other legally recognized losses. Severe gastrointestinal complications or permanent vision impairment may create substantial ongoing treatment needs.

The nature and amount of damages depend on the evidence, applicable law, and outcome of the case. Compensation amounts vary by case. Past results do not guarantee future outcomes.

Speak With a Zepbound Lawsuit Lawyer

If you or a loved one developed gastroparesis, intestinal obstruction/ileus, or NAION after taking Zepbound, a product-liability attorney can review your medical history, treatment records, and diagnosis. A free case review can help determine whether the evidence and applicable law support a potential injury claim.

How Does a Zepbound Lawsuit Work?

1. Free case review. An attorney examines medication exposure, diagnosis, medical history, and available documentation.
2. Investigation. Evidence may include prescription records, diagnostic testing, medical evaluations, and historical drug labeling.
3. Filing. If supported by the evidence and applicable law, legal proceedings may be initiated against potentially responsible parties.
4. Discovery/negotiation. The parties may exchange evidence, consult experts, evaluate medical causation, and discuss settlement.
5. Resolution. A claim may conclude through settlement, dismissal, court ruling, or trial.

Frequently Asked Questions

What is the Zepbound Lawsuit?

The Zepbound Lawsuit refers to product-liability allegations involving serious medical complications following treatment with tirzepatide. Federal proceedings include claims involving gastrointestinal injuries and NAION, but the allegations remain subject to proof.

Can Zepbound cause gastroparesis?

Zepbound delays gastric emptying, and its prescribing information warns about severe gastrointestinal adverse reactions. However, medical evaluation is necessary to determine whether diagnosed gastroparesis is attributable to Zepbound or another cause.

Is intestinal obstruction listed as a Zepbound adverse reaction?

Yes. Zepbound’s prescribing information lists intestinal obstruction and ileus among postmarketing adverse reaction reports, while explaining that such reports cannot reliably establish frequency or causation.

Is NAION linked to Zepbound?

On November 9, 2026, the FDA announced a potential increased NAION risk across GLP-1 medications, including Zepbound. The regulatory finding does not establish that tirzepatide caused an individual patient’s vision loss.

What should I do if I experience sudden vision loss?

Sudden, painless vision loss requires immediate medical evaluation because several serious eye and neurological conditions can produce similar symptoms. An ophthalmologist can determine whether NAION or another condition is responsible.

Can I file a Zepbound Lawsuit for intestinal blockage or NAION?

A patient with a medically documented injury following Zepbound treatment may have a potential claim if the evidence and applicable law support liability. Eligibility requires individualized assessment of medication exposure, diagnosis, causation, damages, and filing deadlines.

Is there a Zepbound lawsuit settlement?

The verified federal court records establish coordinated litigation but do not establish a guaranteed settlement or compensation program. Any particular settlement announcement, trial outcome, or current litigation status should be confirmed through court records.

References

1. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
2. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&type=display
3. https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/25md3163_cm-ord_12.pdf
4. https://www.govinfo.gov/content/pkg/USCOURTS-paed-2_24-md-03094/pdf/USCOURTS-paed-2_24-md-03094-8.pdf